Organoids and organs-on-a-chip

Current State

Organoids and organs-on-a-chip (OOC) represent a significant leap from traditional 2D cell cultures, offering more physiologically relevant models for studying human biology and disease (Jensen et al., 2020; Zheng et al., 2021). Organoids are self-organizing 3D structures derived from stem cells that recapitulate key aspects of organ structure and function (Sachs et al., 2019). OOC systems integrate microfluidics with 3D tissue models to mimic the dynamic microenvironment of organs, including mechanical stimulation and tissue interfaces (Wu et al., 2020; Zhang et al., 2017). These technologies are increasingly applied in drug screening, toxicology, disease modeling, and personalized medicine (Cui et al., 2018; Vlachogiannis et al., 2018).

Strongest Evidence

Evidence strongly supports the utility of these models in various applications. Microfluidic intestine chips, for instance, enable detailed analysis of cellular, chemical, and physical parameters, and allow co-culture with the microbiome, offering capabilities beyond conventional systems (Bein et al., 2018). Advances in hydrogels and extracellular matrix (ECM) derived from decellularized tissues are crucial for providing biomimetic environments that support organoid growth and function, moving towards more standardized and GMP-compliant systems (Liu et al., 2019; Giobbe et al., 2019). Patient-derived organoids (PDOs) have shown promise in modeling treatment responses for metastatic gastrointestinal cancers, demonstrating high similarity to original patient tumors (Vlachogiannis et al., 2018).

Unresolved Uncertainties

Despite rapid progress, several challenges persist. The reliance on animal-derived matrices like Matrigel for organoid culture raises concerns about reproducibility and clinical translation, prompting efforts to develop animal-free alternatives (Kozlowski et al., 2021). Achieving long-term stability and maintaining complex organ functions in vitro remains a hurdle. Furthermore, fully integrating multiple organ systems on a single chip to model systemic interactions and drug metabolism accurately is still an area of active research. Standardization of protocols and characterization methods across different labs is also crucial for broader adoption and comparability of results (Park et al., 2019).

Why the Topic Matters

Organoids and OOC are pivotal for advancing biomedical research by providing more accurate and predictive in vitro models, thereby reducing reliance on animal testing and accelerating drug discovery and development. They hold immense potential for personalized medicine, allowing for patient-specific disease modeling and drug efficacy testing. These technologies are transforming our understanding of human physiology and disease mechanisms, paving the way for novel diagnostics and therapies.

Points of Agreement

• Organoids and organs-on-a-chip (OOC) are recognized as significant technological advancements for creating 3D human tissue and organ models, surpassing limitations of conventional 2D cultures (Liu et al., 2019; Zhang et al., 2017).
• These systems are vital for studying human physiology and pathophysiology, offering new capabilities for drug screening, toxicology, and personalized medicine (Bein et al., 2018; Cui et al., 2018).
• Microfluidic technology is integral to OOC systems, enabling precise control over the cellular microenvironment and facilitating complex biological analyses (Bein et al., 2018; Zhang et al., 2017).
• Hydrogels and advanced materials are crucial for constructing biomimetic 3D environments that support the development and function of organoids and OOCs (Liu et al., 2019).

Active Disagreements

• No active disagreements were identified in the provided abstracts.

Uncertain Claims

• The full extent to which OOC models can perfectly recapitulate all aspects of in vivo human organ function, especially long-term interactions and systemic effects, remains an area of ongoing investigation.
• The standardization of OOC platforms and protocols across different research groups is still evolving, which can impact reproducibility and comparability of results.

Evidence Gaps

• More comprehensive studies are needed to validate OOC models against a wider range of clinical outcomes and drug responses to fully establish their predictive power.
• There is a need for further development in integrating multiple OOCs to create multi-organ systems that can model complex physiological interactions and systemic drug effects.
• Longitudinal studies are required to assess the stability and functional longevity of organoids and OOCs over extended periods, which is crucial for chronic disease modeling and long-term drug testing.

Claim 1: Organoids and organs-on-a-chip (OOC) provide advanced in vitro models for studying human physiology and disease.

Evidence Strength: Strong

Supporting Evidence: Multiple reviews highlight OOCs and organoids as significant breakthroughs, evolving from developmental biology and bioengineering principles to revolutionize biomedical research and drug discovery (Liu et al., 2019; Zheng et al., 2021). These systems offer biomimetic compositions, architectures, and functions, surpassing conventional planar cell cultures (Zhang et al., 2017). Specifically, microfluidic intestine chips enable analysis of individual cellular, chemical, and physical parameters, which is not possible with traditional systems (Bein et al., 2018). They are also recognized for their potential in pharmaceutical analysis, including drug screening and metabolism studies (Cui et al., 2018).

Limitations: While these models offer significant advantages, fully replicating the complexity of in vivo organs, including vascularization, innervation, and immune cell integration, remains a challenge. The scalability and standardization of these systems for high-throughput applications are also ongoing areas of development.

Claim 2: OOC systems can integrate multisensor technologies for automated and continual monitoring of organoid behaviors.

Evidence Strength: Moderate

Supporting Evidence: Research demonstrates the development of multisensor-integrated OOC platforms designed for automated and continual in situ monitoring of organoid behaviors (Zhang et al., 2017). These platforms aim to recapitulate important biological and physiological parameters, making them viable for personalized medicine and drug screening.

Limitations: While the integration of sensors is promising, the complexity of real-time, comprehensive monitoring across various physiological parameters in a robust and scalable manner is still under active development. The reliability and long-term stability of integrated sensors within the biological environment require further validation.

Recent trends in organoids and organs-on-a-chip (OOC) highlight a strong drive towards creating more physiologically relevant and functional in vitro models. A significant development is the increasing sophistication of biomaterials used in these systems. Hydrogels, for instance, are being engineered to provide tunable mechanical and biochemical cues, crucial for recapitulating the native extracellular matrix (ECM) environment (Liu et al., 2019). Furthermore, researchers are exploring ECM hydrogels derived from decellularized tissues to offer a more tissue-specific environment for organoid culture, aiming for GMP-compliant systems for clinical applications (Giobbe et al., 2019). There is also a notable trend towards reducing reliance on animal-derived components like Matrigel in organoid culture, addressing limitations in reproducibility and clinical translation (Kozlowski et al., 2021).

Technological advancements are integrating OOC with microfluidics and multisensor platforms. Microfluidic intestine chips, for example, allow for precise control over cellular, chemical, and physical parameters, enabling co-culture with the microbiome for extended periods (Bein et al., 2018). Multisensor-integrated OOC platforms are emerging for automated and continuous in situ monitoring of organoid behaviors, enhancing their utility for personalized medicine and drug screening (Zhang et al., 2017). These systems are seen as a bridge between preclinical animal models and human physiology, offering new capabilities not possible with conventional 2D or even basic organoid cultures (Zhang et al., 2017; Wu et al., 2020).

The application landscape is expanding, with a particular focus on personalized medicine and drug development. Patient-specific organoids and OOC are being developed, often combining 3D cell culture with 3D printing and numerical simulation, to advance understanding of basic biology and clinical treatments (Zheng et al., 2021). Patient-derived organoids (PDOs) are showing promise as robust preclinical models for predicting treatment responses in metastatic gastrointestinal cancers, demonstrating high similarity to original patient tumors in phenotypic and genotypic profiling (Vlachogiannis et al., 2018). The shift from 2D to 3D cell culture is increasingly recognized as essential for more accurate data on cell-to-cell interactions and tumor characteristics (Jensen et al., 2020). Long-term expanding human airway organoids are also being established for disease modeling, such as cystic fibrosis, allowing for assessment of CFTR function (Sachs et al., 2019). Microfluidic chip technology is also being applied in pharmaceutical analysis for drug screening, active testing, and metabolism studies (Cui et al., 2018).

Emerging methods include the development of "organoids-on-a-chip," which combine the self-organizing capabilities of organoids with the controlled microenvironment of OOC technology, addressing the need for innovative engineering approaches for organoid production, control, and analysis (Park et al., 2019). These trends collectively point towards more complex, integrated, and clinically relevant in vitro models.

Synthesis

Organoids and organs-on-a-chip (OOCs) represent a paradigm shift from traditional two-dimensional (2D) cell cultures to three-dimensional (3D) models that more accurately mimic human organ physiology and pathophysiology (Jensen et al., 2020; Wu et al., 2020). Organoids are self-organizing 3D structures derived from stem cells that recapitulate key aspects of organ architecture and function (Sachs et al., 2019). OOCs are microfluidic devices that engineer the cellular microenvironment, including tissue interfaces and mechanical forces, to simulate organ-level functions (Bein et al., 2018). While organoids excel at mimicking developmental processes, OOCs provide precise control over physiological parameters. A growing trend is the integration of these technologies, creating "organoids-on-a-chip" that combine the biological complexity of organoids with the controlled microenvironment of microfluidics (Park et al., 2019; Zheng et al., 2021).

Methods and Materials

Development of these models relies on advances in stem cell biology, microfabrication, and biomaterials. Hydrogels are critical for providing the 3D scaffold necessary for cell growth and organization (Liu et al., 2019). Traditionally, Matrigel, a poorly defined substance derived from mouse sarcoma cells, has been the standard. However, research is moving towards defined, synthetic hydrogels or extracellular matrix (ECM) hydrogels derived from decellularized tissues to improve reproducibility and facilitate clinical translation (Kozlowski et al., 2021; Giobbe et al., 2019). Microfluidic chip technology enables the precise control of fluid flow, nutrient gradients, and mechanical stimuli, which are crucial for simulating physiological conditions (Bein et al., 2018). Furthermore, integrating multi-sensor systems into OOC platforms allows for continuous, real-time monitoring of organoid behavior and physiological responses (Zhang et al., 2017).

Applications

Organoids and OOCs are transforming biomedical research and pharmaceutical development. They serve as powerful platforms for:

• Disease Modeling: Creating human-relevant models for genetic disorders like cystic fibrosis (Sachs et al., 2019) and metastatic cancers, enabling the study of disease progression and treatment response (Vlachogiannis et al., 2018).
• Drug Discovery and Toxicology: Providing high-throughput screening platforms for assessing drug efficacy and toxicity, potentially reducing reliance on animal models (Cui et al., 2018; Wu et al., 2020).
• Personalized Medicine: Patient-derived organoids (PDOs) can be used to test individual drug responses, guiding clinical treatment decisions for conditions like gastrointestinal cancers (Vlachogiannis et al., 2018; Zheng et al., 2021).
• Physiology Research: Intestine-on-a-chip models, for example, allow for the study of host-microbiome interactions and nutrient absorption under controlled conditions (Bein et al., 2018).

Limitations

Despite their potential, these technologies face several challenges. A major limitation is the widespread use of undefined animal-derived matrices like Matrigel, which introduces variability and hinders clinical applications (Kozlowski et al., 2021). Other challenges include the lack of vascularization in many models, which limits their size and long-term viability, and difficulties in achieving the full cellular complexity and maturity of adult organs. Standardization and scalability also remain significant hurdles for widespread adoption in industrial and clinical settings (Park et al., 2019).

Update Triggers

This review should be updated upon the emergence of:

• Clinically-approved therapies developed or validated using organoid or OOC platforms.
• Standardized, GMP-compliant synthetic matrices that successfully replace Matrigel for a wide range of organoid types.
• Development of fully vascularized and multi-organ systems that achieve long-term culture and systemic physiological responses.
• Integration of advanced AI and sensor technologies for automated, high-throughput analysis and prediction of clinical outcomes.

Near-Term Work (1-3 Years)

• Standardization of Culture Conditions: Develop fully defined, synthetic, and scalable hydrogels to replace Matrigel, ensuring reproducibility and GMP compliance for clinical applications (Kozlowski et al., 2021; Giobbe et al., 2019). This includes creating tissue-specific extracellular matrix (ECM) formulations.
• Integration of Real-Time Sensing: Incorporate non-invasive, multi-modal sensors (e.g., for transepithelial electrical resistance (TEER), oxygen, pH, metabolites) directly into organ-on-a-chip (OOC) platforms for continuous monitoring of organoid health and function (Zhang et al., 2017).
• Advanced Biofabrication: Utilize 3D printing and advanced microfluidics to create more complex, multi-cellular architectures that better mimic native tissue organization and vascularization (Zheng et al., 2021).
• Organoid-OOC Integration: Systematically combine the self-assembly advantages of organoids with the microenvironmental control and perfusion of OOC systems to create more physiologically relevant "organoids-on-a-chip" (Park et al., 2019).

Validation Needs

• Functional Benchmarking: Establish standardized functional assays to validate that these models recapitulate specific organ functions (e.g., metabolic activity for liver organoids, barrier function for intestine chips). Benchmarks should be based on primary human tissue data.
• Predictive Validity: Conduct systematic comparisons of drug responses in organoid/OOC models against retrospective and prospective clinical trial data to establish their predictive power for efficacy and toxicity (Vlachogiannis et al., 2018).
• Cross-Platform Validation: Compare results from different organoid and OOC models of the same tissue to understand inter-model variability and define best practices.

Datasets and Benchmarks

• Public Omics Repository: Create a centralized, open-access database of genomic, transcriptomic, and proteomic data from various organoid and OOC models, cross-referenced with primary human tissue data.
• Reference Drug Response Library: Develop a benchmark dataset of responses to a panel of well-characterized compounds (with known efficacy and toxicity profiles) across multiple standardized patient-derived organoid lines.

Translation Barriers

• Scalability and Cost: Current methods are often low-throughput, labor-intensive, and expensive, hindering their adoption for large-scale drug screening (Wu et al., 2020).
• Lack of Standardization: The variability in cell sources, culture media (e.g., Matrigel), and platform design makes it difficult to compare results across different labs (Kozlowski et al., 2021).
• Regulatory Acceptance: A clear framework for validating and qualifying these models for regulatory submission (e.g., to the FDA) is still under development.
• Incomplete Biological Complexity: Models often lack immune components, a functional microbiome, and vascular perfusion, limiting their ability to model systemic diseases and complex drug metabolism (Bein et al., 2018).

High-Value Experiments

• Multi-Organ Systems: Develop and validate integrated multi-organ-on-a-chip systems (e.g., gut-liver-kidney) to study systemic drug metabolism, toxicity, and inter-organ crosstalk in diseases like cancer metastasis.
• Personalized Medicine Trials: Conduct proof-of-concept studies using patient-derived organoids (PDOs) to predict individual patient responses to therapies in a co-clinical trial setting, comparing PDO predictions with actual patient outcomes (Vlachogiannis et al., 2018).
• Modeling Host-Microbiome Interactions: Use intestine-on-a-chip models to co-culture human intestinal cells with complex, patient-derived gut microbiomes to study their role in health, disease, and drug metabolism over extended periods (Bein et al., 2018).